ArticleHealth science reports2026
Strengthening Pharmacogenomics Implementation in Africa: Challenges and Opportunities - A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The discipline of pharmacogenomics (PGx) studies the influence of genetic diversity on drug response, bringing the potential to personalized treatment and reduction of adverse effects. Although PGx integration into healthcare is progressing at a global scale, its implementation in Africa faces unique challenges and opportunities. The purpose of this review was to evaluate the status of PGx in Africa, outlining the challenges to its integration into healthcare systems and highlighting available opportunities for improving personalized medicine across the continent. Methods: A narrative review was conducted by retrieving relevant literature from PubMed, Google Scholar, and websites for African health agencies. The search identified 91 records, of which duplicates were removed. Thereafter, 58 papers underwent full-text evaluation resulting in 39 relevant articles and policy reports. Articles were considered based on their relevance to the objectives of this review and publication year range (2020-2025). Studies without full text, focusing on continents other than Africa, or published outside the defined period were excluded. Results: Significant challenges hinder PGx integration in Africa. Technical barriers include inadequate laboratory infrastructure, insufficient sequencing capacity, and underrepresentation in genomic studies globally. Policy challenges include the absence of context-specific regulatory frameworks, and data security measures, while socioeconomic barriers entail limited research funding and low public awareness. Besides, emerging digital health infrastructure, especially mobile health tools, brings innovative pathways for PGx adoption. Additionally, local disease priorities such as malaria, HIV/AIDS and tuberculosis provide clear targets for impactful PGx research. Regional and diaspora partnerships are building capacity, biobanks, and knowledge-sharing platforms. Conclusion: Africa's path to PGx integration requires coordinated strategies that combine policy adoption, education, research equity, and sustainable investment. With continental collaboration, PGx promises to improve health systems and enhance treatment outcomes in Africa. Clinical Trial Number: Not Applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.